KINISKA PHARMACEUTICALS ($KNSA) posted quarterly earnings results for Q1 2026 on Tuesday, April 28th. The company reported earnings of $0.27 per share, beating estimates of $0.21 by $0.06. The company also reported revenue of $214,270,000, beating estimates of $210,213,330 by $4,056,670.
You can see Quiver Quantitative's $KNSA stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
KINISKA PHARMACEUTICALS Insider Trading Activity
KINISKA PHARMACEUTICALS insiders have traded $KNSA stock on the open market 24 times in the past 6 months. Of those trades, 0 have been purchases and 24 have been sales.
Here’s a breakdown of recent trading of $KNSA stock by insiders over the last 6 months:
- MARK RAGOSA (CHIEF FINANCIAL OFFICER) has made 0 purchases and 6 sales selling 92,686 shares for an estimated $3,871,213.
- BARRY D QUART has made 0 purchases and 7 sales selling 45,790 shares for an estimated $2,028,239.
- JOHN F. PAOLINI (CHIEF MEDICAL OFFICER) has made 0 purchases and 3 sales selling 40,000 shares for an estimated $1,792,939.
- EBEN TESSARI (CHIEF OPERATING OFFICER) has made 0 purchases and 4 sales selling 24,718 shares for an estimated $1,023,516.
- SANJ K PATEL (CHAIRMAN & CEO) sold 7,278 shares for an estimated $363,972
- MICHAEL R MEGNA (CHIEF ACCOUNTING OFFICER) sold 6,625 shares for an estimated $309,321
- ROSS MOAT (CHIEF OPERATING OFFICER) has made 0 purchases and 2 sales selling 4,070 shares for an estimated $194,501.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.
KINISKA PHARMACEUTICALS Hedge Fund Activity
We have seen 116 institutional investors add shares of KINISKA PHARMACEUTICALS stock to their portfolio, and 92 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ROCKEFELLER CAPITAL MANAGEMENT L.P. added 6,980,879 shares (+4025.0%) to their portfolio in Q4 2025, for an estimated $287,961,258
- FMR LLC added 843,108 shares (+105.4%) to their portfolio in Q4 2025, for an estimated $34,778,205
- RUBRIC CAPITAL MANAGEMENT LP removed 671,347 shares (-16.8%) from their portfolio in Q4 2025, for an estimated $27,693,063
- VICTORY CAPITAL MANAGEMENT INC added 512,163 shares (+inf%) to their portfolio in Q4 2025, for an estimated $21,126,723
- FAIRMOUNT FUNDS MANAGEMENT LLC removed 453,151 shares (-25.6%) from their portfolio in Q4 2025, for an estimated $18,692,478
- SOLEUS CAPITAL MANAGEMENT, L.P. added 437,000 shares (+291.3%) to their portfolio in Q4 2025, for an estimated $18,026,250
- CITADEL ADVISORS LLC added 427,562 shares (+135.9%) to their portfolio in Q4 2025, for an estimated $17,636,932
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.
KINISKA PHARMACEUTICALS Price Targets
Multiple analysts have issued price targets for $KNSA recently. We have seen 3 analysts offer price targets for $KNSA in the last 6 months, with a median target of $58.0.
Here are some recent targets:
- David Nierengarten from Wedbush set a target price of $58.0 on 04/16/2026
- Eva Fortea Verdejo from Wells Fargo set a target price of $53.0 on 02/25/2026
- Edward Nash from Canaccord Genuity set a target price of $62.0 on 02/19/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
